An innovative “one-size-fits-all” vaccine targeting a common genetic mutation has demonstrated encouraging results in an early-stage clinical trial aimed at preventing the return of pancreatic cancer, one of the most lethal and treatment-resistant cancers.
Pancreatic cancer carries a grim prognosis, with a five-year survival rate of approximately 13%, and recurrence rates reaching as high as 80%. Addressing this urgent need, researchers at the University of California, Los Angeles (UCLA) conducted a Phase 1 trial focusing on a vaccine designed to stimulate the immune system against KRAS gene mutations—a mutation present in roughly 90% of pancreatic cancers and a significant fraction of other cancers, including colorectal.
“The disease most in need of a preventative therapy for recurrence is pancreatic cancer,” stated Dr. Zev Wainberg, co-director of UCLA’s gastrointestinal oncology program and co-leader of the trial.
KRAS mutations, once deemed undruggable, serve as a prime target for this novel vaccine. It uses synthetic peptide chains to train the immune system to recognize and destroy cells harboring these mutations. Unlike personalized vaccines that require tumor sequencing and customization, this vaccine is off-the-shelf and ready for broad application.
The trial enrolled 25 patients—20 with pancreatic cancer and 5 with colorectal cancer—each confirmed to have KRAS mutations and who had undergone standard treatments including surgery and chemotherapy. Despite these treatments, microscopic residual disease—undetectable cancer cells left behind—remains a major cause of recurrence.
“We are dealing with cancer cells so small they cannot be seen on scans,” explained Dr. Scott Kopetz from MD Anderson Cancer Center.
After surgery, participants received up to six initial doses of the vaccine, ELI-002 2P, with some also receiving booster shots over six months. Approximately 85% of patients developed an immune response targeting KRAS mutations, and nearly two-thirds showed a robust response sufficient to potentially eliminate residual cancer cells. Remarkably, nearly 70% also exhibited immune activity against additional tumor targets not included in the vaccine, with some “super-responders” demonstrating exceptionally strong immune reactions.
“These patients experienced the best outcomes,” noted Dr. Wainberg. The team is now progressing to a randomized Phase 2 trial to further evaluate vaccine efficacy and durability compared to standard monitoring.
In this initial trial, pancreatic cancer patients survived on average 29 months and remained free of recurrence for over 15 months post-vaccination—significantly surpassing typical outcomes for surgically resectable cases.
Advances in mRNA technology and faster gene sequencing have revitalized cancer vaccine development, overcoming previous challenges related to immune activation and safety. This vaccine’s lipophilic peptide design, featuring a “tail” that anchors in lymph nodes to boost immune response, represents a novel improvement over earlier peptide vaccines.
Though further studies are needed to confirm these findings, the success of this KRAS-targeting vaccine marks a promising step toward off-the-shelf immunotherapies for difficult cancers. Memorial Sloan Kettering is concurrently developing similar universal vaccines for other mutations, underscoring a potential new frontier in cancer treatment.
“The strong correlation between T-cell response and long-term survival suggests this vaccine can effectively target KRAS mutations,” said Stephanie Dougan of Dana-Farber Cancer Institute. “This is a highly exciting development in cancer immunotherapy.”
READ MORE
